Pulmonary Vascular Changes in Acute Respiratory Distress Syndrome due to COVID-19

Jha, Ajay Kumar

doi:10.1164/rccm.202009-3508le

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our hypothesis would be that, in relation to the parenchymal (“ground-glass” and “dense” opacifications) and vascular pulmonary involvement (markedly impaired pulmonary perfusion, caused by pulmonary angiopathy and thrombosis) that occurs during the acute phase of pneumonia [ 5 , 6 ], an increase in PVR develops, with a consequent onset of PH [ 7 ]. RV normally works at an extremely low level of afterload, and the muscle thickness of its free wall is not particularly conspicuous.…”

mentioning

confidence: 99%

Pulmonary arterial hypertension and right ventricular systolic dysfunction in COVID-19 survivors

et al. 2022

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Pulmonary arterial hypertension and right ventricular systolic dysfunction in COVID-19 survivors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…6 The viral load reaches its peak in the respiratory tract and it remains unclear if virus persistence in the gut is a driver of aggressive damage during COVID-19 progression. 31 Since the viral load increases relatively linearly, even after the active phase, viral RNA are still detectable after a patient has died. 32 A persistent infectious environment can potentially lead to dendritic cell damage or incomplete maturation and thereby impair T cell activation, even with a sufficient viral load to activate immune response.…”

Section: Clinical Manifestations and Epidemiologymentioning

confidence: 99%

Genomic variation, origin tracing, and vaccine development of SARS-CoV-2: A systematic review

Huang

Guo

et al. 2021

The Innovation

View full text Add to dashboard Cite

COVID-19 has spread globally to over 200 countries with more than 40 million confirmed cases and one million deaths as of November 1, 2020. The SARS-CoV-2 virus, leading to COVID-19, shows extremely high rates of infectivity and replication, and can result in pneumonia, acute respiratory distress, or even mortality. SARS-CoV-2 has been found to be continue rapidly evolving, with several genomic variants emerging in different regions throughout the world. In addition, despite intensive study of the spike protein, its origin and molecular mechanisms in mediating host invasion are still only partially resolved. Finally, the repertoire of drugs for COVID-19 treatment is still limited, with several candidates still under clinical trial and no effective therapeutic yet reported. Although vaccines based on either DNA/mRNA or protein have been deployed, their efficacy against emerging variants requires ongoing study, with multivalent vaccines supplanting the first generation vaccines due to their low efficacy against new strains. Here, we provide a systematic review of studies on the epidemiology, immunological pathogenesis, molecular mechanisms and structural biology, as well as approaches for drug or vaccine development for SARS-CoV-2.

show abstract

Pulmonary Vascular Changes in Acute Respiratory Distress Syndrome due to COVID-19

Cited by 2 publications

References 5 publications

Pulmonary arterial hypertension and right ventricular systolic dysfunction in COVID-19 survivors

Pulmonary arterial hypertension and right ventricular systolic dysfunction in COVID-19 survivors

Genomic variation, origin tracing, and vaccine development of SARS-CoV-2: A systematic review

Contact Info

Product

Resources

About